
Opinion|Videos|January 7, 2026
Sonrotoclax in R/R Mantle Cell Lymphoma After BTKi
Author(s)Marc S. Hoffmann, MD
New findings reveal promising advancements in treating relapsed mantle cell lymphoma with BCL-2 inhibitors and novel agents, enhancing patient outcomes.
Advertisement
Marc S. Hoffmann, MD, discusses initial results from a phase 1/2 study exploring the investigational next-generation BCL2 inhibitor sonrotoclax in patients with relapsed/refractory mantle cell lymphoma (MCL) previously treated with a BTK inhibitor. Hoffmann highlights response outcomes from single-agent sonrotoclax treatment, with particular emphasis on the durability of the responses. He also explains the next steps with sonrotoclax in MCL.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Lung Cancer News Roundup: June 2026
2
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
3
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































